Harbour BioMed

Harbour BioMed, a cancer therapies company has acquired Harbour Antibodies from Erasmus MC Holding, Atlas Holding and other shareholders. Harbour Antibodies focuses on the production of antibodies and VH (heavy chain with one variable) domains for therapy. With this acquisition, Harbour BioMed plans to expand its presence in the Boston area by establishing a drug discovery innovation centre.

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.